Freedom to Operate
Judges Deny Challenge to Psilocybin Patent
The Patent Trial and Appeal Board decided that petitions against Compass Pathways' psilocybin patents would not move forward to trial.
Can the Clever Use of Old Legal Strategies Thwart Psychedelic Monopolies?
Corporations are going to use IP law to profit from psychedelics. But creative strategies from other industries could help people push back against exclusionary ownership and keep drugs accessible.
New Filing Challenges Compass Pathways’ Infamous Patent on Synthetic Psilocybin
The non-profit Freedom to Operate used research from chemists and crystallographers to argue in a legal filing that Compass’ form of synthetic psilocybin is not a new invention.
Advertisement
Advertisement
Advertisement